Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Defines medical necessity and coverage stance for transcutaneous, functional, and neuromuscular electrical stimulation modalities for members in the State of Nebraska; identifies devices and therapies considered unproven and not medically necessary.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Added HCPCS codes A4543, A4544, E0721, and E0743 to the policy's applicable codes.
Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.
Updated related policy links to reflect current policy titles for implanted spinal cord stimulators and occipital nerve procedures.
Nebraska-onlygeographic applicability
4HCPCS codes added
mixedevidence strength for SCI & FES
multiple
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
FES is medically necessary as part of comprehensive ambulation rehabilitation for lower limb paralysis due to spinal cord injury when ALL of the following are met:
FES eligibility criteria: Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves)
FES eligibility criteria: Muscle and joint stability for weight bearing at upper and lower extremities with balance and control to maintain an upright support posture independently
FES eligibility criteria: Demonstration of brisk muscle contraction
FES eligibility criteria: Demonstration of sensory perception sufficient for muscle contraction
FES eligibility criteria: High level of motivation, commitment, and cognitive ability for device use
FES eligibility criteria: Ability to transfer independently
FES eligibility criteria: Demonstration of independent standing tolerance for at least 3 minutes>= 3 minutes
FES eligibility criteria: Demonstration of hand and finger function to manipulate controls
FES eligibility criteria: Post-recovery from SCI and restorative surgery of at least 6 months>= 6 months
FES eligibility criteria: Absence of hip and knee degenerative disease
FES eligibility criteria: Absence of history of long bone fracture secondary to osteoporosis
TENS and NMES — Conditional Coverage
TENS and NMES: considered medically necessary in certain circumstances; refer to Nebraska DHHS DMEPOS Code 471-7-000 for clinical coverage criteria.
TENS/NMES reference: Coverage depends on meeting Nebraska DHHS DMEPOS durable medical equipment clinical coverage criteria
Policy defers to state DMEPOS criteria
Not Medically Necessary — Unproven Modalities
The following electrical stimulation modalities are considered unproven and not medically necessary due to insufficient evidence of efficacy:
Unproven modalities: Percutaneous electrical nerve field stimulation (PENFS)
Unproven modalities:
Evidence summaries by condition
Evidence summaries and conclusions for specific conditions:
SCI - home-based FES evidence: Hayes EARB concluded insufficient peer-reviewed literature and no/unclear support for home-based FES for rehabilitation following SCI.
limited abstracts and low quantity evidence
SCI - hybrid FES cycling: Systematic review (Máté et al. 2023) found hybrid FES cycling moderately more effective than arm crank ergometry for V̇o2peak and emerging evidence of aerobic fitness benefit but noted small study sizes and heterogeneity.
meta-analysis of small studies
SCI - NMES/FES training body composition: Bekhet et al. (2022) reported average 26% increase in muscle cross-sectional area across studies but noted heterogeneous interventions and recommended multicenter RCTs.
mixed study designs and small samples
Evidence synthesis summary (no explicit coverage rules provided in these chunks)
evidence_summary: Multiple systematic reviews and HTAs report low-to-moderate quality evidence overall with heterogeneous results: some trials show improvements in gait parameters, walking distance, trunk control or quality-of-life in specific populations or when combined with supervised therapy, but other RCTs show no significant functional benefit; long-term durability and optimal parameters remain unclear.
See individual study summaries in cited HTAs and reviews.
Evidence-linked condition groups
Evidence indicates potential coverage when specific clinical outcomes or settings are supported by trials showing benefit; conversely lack of benefit suggests noncoverage unless individualized justification provided.
Heart failure (FES): FES of the legs has RCT and meta-analytic evidence showing improvements in peak VO2, 6-minute walk distance, and quality of life in patients with chronic heart failure; some RCTs report reduced HF-related hospitalizations after FES training.based on RCTs/meta-analyses
Benefits vary vs conventional exercise; study limitations include small sizes and heterogeneity
Postoperative musculoskeletal rehabilitation (NMES): NMES applied to quadriceps as an adjunct to standard rehabilitation demonstrated improved early quadriceps strength and functional performance after total knee arthroplasty in RCTs; effects most pronounced early and may persist up to 1 year for some measures.early initiation (e.g., within 48 hours after TKA) and protocol-based durations
Evidence limited by small trials
Indications with supporting evidence
Evidence-supported indications and contexts where NMES demonstrated potential benefit in trials and reviews
Pediatric unilateral spastic cerebral palsy: Daily NMES-assisted gait to ankle dorsiflexors for eight weeks increased muscle volume and dorsiflexion strength in children with unilateral spastic CP (RCT).8 weeks
Changes were use-dependent and diminished after treatment cessation
Post-stroke dysphagia: NMES combined with swallowing therapy improved swallowing function and quality of life in multiple RCTs and meta-analyses (46 RCTs, 3,346 participants) with treatment courses from 2–12 weeks; recommended as adjunct to conventional swallowing therapy.2–12 weeks
Heterogeneous protocols and limited adverse event reporting
Post-stroke motor recovery: NMES and variants (e.g., CCFES) can improve ADLs, walking parameters, and some upper-extremity outcomes particularly in subacute stage or severe paresis; evidence is mixed for overall functional motor ability.
Coverage-relevant evidence summaries
Evidence-based summaries and implications for coverage decisions (document provides mixed and condition-specific findings):
Hospitalized/ICU NMES: NMES shows small-to-moderate effects on muscle size and strength and mixed effects on function; some RCTs demonstrate mitigation of postsurgical muscle weakness when applied early post-op, but heterogeneity and small study sizes limit conclusions.
May be considered in selected populations where trials show benefit
NMES for swallowing (dysphagia): Systematic reviews report positive signals for NMES combined with swallowing therapy but overall evidence quality ranges from low to very low; use as an adjunct or under governance/research arrangements is recommended.
Heterogeneous protocols and limited adverse event reporting
NMES to prevent ICU-acquired weakness: Meta-analyses suggest improvements in muscle strength and ventilation/ICU LOS in some studies but functional status and mortality effects are inconsistent across trials.
Protocol- and population-dependent outcomes
Evidence summaries (informational for coverage)
Evidence summary relevant to coverage decisions (no explicit coverage criteria provided in these sections):
IFT evidence: Systematic reviews/meta-analyses show IFT may reduce pain versus placebo immediately post-treatment but findings are heterogeneous and no added benefit when combined with standard care versus standard care alone.
Supports cautious/limited coverage; see NICE recommendations against routine use for knee OA and chronic primary pain
MENS/MET evidence: Small RCTs and meta-analyses report modest short-term pain reductions for some myofascial conditions but evidence is limited and longer-term benefit uncertain.
Evidence insufficient for broad unrestricted coverage
PENS/TEAS evidence: PENS shows immediate moderate effects on pain thresholds; TEAS in perioperative RCTs reduced short-term pain and opioid use—evidence heterogeneous and often short-term.
May justify short-term or targeted use in selected patients
Coverage-relevant evidence statements
Evidence-based conclusions and common coverage-relevant inferences drawn from systematic reviews and trials in the document:
PENS general evidence summary: Systematic reviews identify small, heterogeneous trials; PENS shows mild-to-moderate immediate short-term effects on local mechanical hyperalgesia but effects are often not sustained long-term; quality of evidence is low to very low.
Further high-quality RCTs recommended
TEAS perioperative evidence: TEAS demonstrates reduced postoperative pain scores within 24 hours, reduced postoperative opioid use, and lower PONV rates in meta-analyses and multicenter RCTs; benefits are primarily early recovery metrics.
May be considered as adjunct in perioperative care
PENFS pediatric evidence: Observational registries and small studies report symptom and functional improvements in pediatric DGBI with PENFS, but lack of controls and short follow-up limit conclusions.
Evidence weak and further placebo-controlled trials needed
Evidence synthesis / coverage stance
Summary of coverage-relevant conclusions from evidence:
PENFS evidence: PENFS shows short-term symptom improvement in pediatric functional abdominal pain and related disorders in small RCTs and observational studies, but limitations (small samples, single-center, short follow-up, lack of blinding) exist; further larger placebo-controlled trials are recommended.
See trial details in referenced studies
PNS evidence: PNS may reduce pain and improve function in some settings (post-TKA, chronic low back pain, peripheral neuropathic pain) with several small RCTs and case series reporting clinically meaningful responses, but overall evidence quality is low to insufficient and additional large randomized trials are needed.
Evidence heterogeneous across indications
PES/PEMF evidence: Evidence is insufficient to support PES/PEMF for treatment of pain; available studies are small and heterogeneous and more robust randomized trials are needed.
Not supported for routine coverage absent stronger data
Evidence-based coverage considerations
Coverage consideration should reflect the following evidence-based observations
PEMF/PES evidence: High-quality evidence is lacking; studies are heterogeneous with mixed short-term benefits in OA and other conditions; further large RCTs are needed.
PEMF not consistently superior to placebo
Restorative neurostimulation evidence: Limited evidence includes one fair RCT with marginal benefit and multiple pre/post observational studies with some long-term follow-up showing clinically meaningful improvements but at high risk of bias and attrition.
PNS evidence: Percutaneous PNS evidence is small, heterogeneous, and of low quality; larger RCTs comparing PNS to other chronic pain management methods are needed.
Evidence summary and implications for restorative neurostimulation (ReActiv8):
Evidence status: Evidence is inconclusive overall: ECRI found studies with high risk of bias and recommended additional independent studies; one RCT (Gilligan 2021) showed mixed results with modest between-group differences at 120 days and later unblinded therapeutic use for all participants.
Long-term observational follow-up shows durability but is limited by attrition and lack of controls
Typical study entry features: Patients had chronic mechanical low-back pain refractory to >90 days of medical management and at least one attempt of physical therapy; were not surgical candidates>90 days
Reflects Gilligan RCT and Mitchell study inclusion criteria
Scrambler Therapy — evidence & typical protocols
Evidence summary and implications for Scrambler Therapy (ST/TEMPR):
Evidence status: Overall evidence is low to very low quality and heterogeneous; systematic reviews and guideline groups conclude insufficient evidence to recommend routine use outside clinical trials.
Some RCTs and meta-analyses show marginal or short-term pain reduction but methodological limitations and small sample sizes limit conclusions
Typical treatment regimen in studies: Common protocol: 30–50 minute sessions over ~10 working days; follow-up commonly short (10 days to 3 months)
Evidence summary and implications for Translingual Stimulation (PoNS/TLNS):
Evidence status: Evidence is inconclusive; ECRI concluded too few data to determine safety and efficacy though some RCTs showed benefit when TLNS was combined with targeted physical therapy.
Limitations include small samples and single-center trials
Observed clinical use: Studies combine TLNS with targeted physical therapy for balance/gait deficits after mmTBI or chronic balance deficits post-TBI/MS, often showing improvements in SOT and DGI outcomes compared to controls; trials required adjunctive PT.
Adjunctive PT required in study protocols
Clinical contexts from trials and device indications
Clinical contexts described in the document where electrical stimulation was used in trials or has device indications
TLNS/PoNS trial context: Participants had chronic balance/gait deficits after mild-to-moderate TBI, had plateaued after prior physical therapy, and received TLNS plus targeted physical therapy with reported improvements in SOT and DGI.
Adjunctive PT was part of study protocols
ReActiv8 indication context: Device indicated for adults with intractable chronic low back pain associated with multifidus dysfunction who failed therapy including pain medications and physical therapy and are not candidates for spine surgery.
Based on FDA PMA labeling; device targets L2 medial branch.
The policy identifies a set of electrical stimulation modalities that are considered not medically necessary due to insufficient evidence of efficacy. These include Interferential therapy (IFT), Microcurrent electrical nerve stimulation (MENS), Percutaneous electrical nerve stimulation (PENS) and related percutaneous field approaches (PENFS), Percutaneous peripheral nerve stimulation (PNS), Peripheral subcutaneous/nerve field stimulation (PSFS/PNFS), Pulsed electrical stimulation (PES), restorative neurostimulation, scrambler therapy (ST), and translingual stimulation for gait rehabilitation.
A recent Hayes Evidence Analysis Research Brief found that the published peer-reviewed literature on home-based FES for rehabilitation after spinal cord injury (SCI) is limited to abstracts and a single RCT with supporting abstracts; the brief concluded there is no clear support and insufficient evidence to evaluate home-based FES for SCI rehabilitation.
Several device- and technique-specific exclusions or limitations are informed by the available HTAs and evidence reviews: technologies lacking peer‑reviewed clinical studies (for example, manufacturer‑specific systems without published trials) and modalities with consistently low or insufficient quality evidence (e.g., PES/PEMF, many PNS indications, and restorative neurostimulation reports) are treated as unproven and therefore not medically necessary.
High-quality randomized data from critically ill populations (Fossat et al.) showed that adding in‑bed cycling plus electrical stimulation of quadriceps to standardized early ICU rehabilitation did not improve global muscle strength at ICU discharge. Such negative trial results are a basis for cautious use of NMES in routine ICU protocols without additional justification.
For COPD and other chronic pulmonary conditions, the evidence indicates that NMES should not be considered a replacement for pulmonary rehabilitation. Systematic reviews show mixed or limited benefit for peak exercise capacity and health‑related quality of life when NMES is used in isolation, so NMES may be considered only as an adjunct or when standard pulmonary rehabilitation is not feasible.
The policy highlights that specific named devices or manufacturer systems without published clinical studies or guideline support (for example, devices for neuropathic pain where no peer‑reviewed studies were identified) lack evidence to justify coverage and therefore are not supported.
NICE guidance is cited with an explicit recommendation that Interferential Therapy (IFT) should not be offered for knee osteoarthritis and for chronic primary pain because the committee found insufficient evidence of clinical benefit.
Microcurrent electrical nerve stimulation (MENS) has been studied only in small trials and meta‑analyses; available RCTs are limited and heterogeneous. Current evidence is insufficient to conclude consistent safety or efficacy across conditions and does not support routine coverage.
NICE guidance on PENS states that PENS should not be offered for low back pain with or without sciatica due to insufficient evidence of sustained clinical benefit beyond short‑term outcomes; NICE allows PENS in specific neuropathic pain contexts under governance but does not recommend routine use for LBP.
Evidence for PNS and for PES/PEMF is generally small, heterogeneous, and of low quality. Systematic reviews and HTAs conclude that current data are insufficient to support routine use of these modalities for most chronic pain indications.
Multiple systematic reviews find the overall evidence base for PEMF/PES to be inadequate to establish efficacy for chronic pain or joint disease. The policy therefore treats PES/PEMF as unsupported for routine pain management pending higher‑quality randomized trials.
Several modalities (e.g., PENS, PENFS, and various percutaneous approaches) show short‑term or immediate effects in small trials, but the studies are heterogeneous, often single‑center, and lack consistent longer‑term benefit; consequently the evidence is inconclusive and does not support broad coverage without specific justification.
The policy reiterates an important operational principle: FDA clearance or approval alone is not a basis for coverage. Regulatory status is informational; coverage decisions depend on the clinical evidence of effectiveness and durability.
The policy cites multiple HTAs and guidance documents (including NICE and other systematic reviews) as sources informing the evidence assessments for percutaneous electrical nerve stimulation and related modalities; these references are used to contextualize coverage decisions where evidence is limited or conflicting.
This Medical Policy is intended to provide interpretive assistance to payers and providers; it does not replace federal, state, or contractual benefit plan requirements. Coverage determinations must be consistent with applicable federal/state law and the member's benefit plan.
Modalities considered in this policy encompass a broad range of transcutaneous, percutaneous, and implantable interventions. These include FES, NMES, TENS, IFT/IFC, MENS, PENS/PENFS, PNS, PSFS/PNFS, PES/PEMF, restorative neurostimulation (ReActiv8), scrambler therapy, and translingual stimulation (PoNS/TLNS).
Although FES is a covered modality for selected indications (see FES criteria), the policy notes that home‑based FES for SCI rehabilitation lacks sufficient peer‑reviewed evidence and therefore may be considered not medically necessary or limited where evidence is required.
A multicenter RCT by Matsumoto et al. (2023) in post‑stroke patients with foot drop found no statistically significant improvement in barefoot 6‑minute walk distance or walking speed with FES versus training without FES, highlighting that FES does not uniformly demonstrate functional benefit across all post‑stroke cohorts.
The Fossat ICU RCT enrolling 314 critically ill adults reported that adding early in‑bed cycling plus quadriceps electrical stimulation to standardized early rehabilitation did not improve global muscle strength at ICU discharge, indicating negative outcomes for routine NMES augmentation in that ICU population.
Several trials and reviews show that NMES often demonstrates benefit when used as an adjunct to structured rehabilitation, but evidence is limited when NMES is used alone. The policy therefore highlights an evidence gap for NMES applied without concurrent or prior rehabilitation, particularly in chronic conditions such as COPD.
NICE guidance indicates limited or conditional roles for NMES: NMES is not recommended routinely for knee osteoarthritis, and for oropharyngeal dysphagia NMES should only be used with special arrangements for governance, consent and audit or within research settings due to limited evidence.
Interferential therapy and other medium‑frequency modalities show inconsistent incremental benefit when added to standard therapy; pooled analyses suggest possible short‑term pain relief in some indications but overall heterogeneity and small study sizes limit confidence—supporting the policy stance that incremental benefit is unclear.
For chronic low back pain and several musculoskeletal conditions, evidence quality is generally low and reported benefits are often short‑term and of uncertain clinical significance; PENS and related percutaneous approaches are not supported as first‑line therapies based on current guidance.
Multiple systematic reviews conclude that the evidence for PES/PEMF is insufficient to support routine use for chronic pain or tissue repair; available studies are small, heterogeneous, and show inconsistent outcomes.
Given the weak and inconsistent data for PES/PEMF and many PNS indications, the policy does not support these therapies for routine chronic pain management absent higher‑quality RCTs demonstrating clinically meaningful benefit.
Systematic reviews, HTAs, and professional guidelines conclude that evidence for scrambler therapy is low to very low quality and heterogeneous; guideline bodies (ASCO, ESMO) do not recommend routine use for CIPN or chronic pain outside investigational settings.
Device‑ and indication‑specific assessments from ECRI, Hayes, and NICE are cited throughout the policy to inform coverage decisions; these resources identify limited or evolving evidence for certain devices and emphasize the need for larger, independent comparative trials.
Codes, HCPCS, and Device Product Codes
Mixed procedure codes (CPT/CPT® listed)mixed
0278T
Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0720T
Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
0783T
Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650
Percutaneous implantation of neurostimulator electrode array, epidural.
63655
Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663
Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664
Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685
Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
1–10 of 13
1/2
HCPCS and supply codesHCPCS
A4438
Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543
Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544
Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556
Electrodes (e.g., apnea monitor), per pair.
A4557
Lead wires (e.g., apnea monitor), per pair.
A4593
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595
Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
FDA product code referenced for ReActiv8 Implantable Neurostimulation System (PMA)
Regulatory status — PoNSmixed
De Novo
Regulatory pathway for PoNS translingual stimulator (De Novo approval)
Coding resources referencedHCPCS
HCPCS
CMS Functional Electrical Stimulation (FES) coverage and HCPCS coding referenced (specific HCPCS codes not listed in these chunks)
Applicable HCPCS Codes AddedHCPCS
A4543
HCPCS code added (description per code set)
A4544
HCPCS code added (description per code set)
E0721
HCPCS code added (description per code set)
E0743
HCPCS code added (description per code set)
inv-58: Post-recovery duration after SCI/restorative surgery
Post-recovery duration (eligibility)>= 6 months post-recovery from spinal cord injury or restorative surgery
Demonstrated intact neuromuscular unitsEvidence of intact lower motor units (L1 and below) — both muscle and peripheral nerves
Weight-bearing stabilityMuscle and joint stability enabling independent upright support and balance
Prior Authorization, Documentation, and Denial Triggers
Prior Authorization
Prior Authorization, Documentation, and Denial Triggers
Prior authorization may be required for certain device-specific electrical stimulation therapies and for implanted restorative neurostimulation. When prior authorization is requested, clinical documentation must clearly justify medical necessity and address device identification, indication, prior conservative treatments, and expected functional goals. Nebraska providers should consult applicable Nebraska DHHS DMEPOS rules (Code 471-7-000) and verify state- and contract-specific prior authorization requirements before ordering devices or initiating therapy.
Device-specific prior authorization expectation: implanted restorative neurostimulation (e.g., ReActiv8) and some FES systems often require prior auth and detailed documentation.
Prior authorization justification for implanted restorative neurostimulation should include prior conservative management (e.g., physical therapy, medications), documentation of multifidus dysfunction, baseline pain and function measures, and rationale why patient is not a surgical candidate.
Prior authorization may require indication and prior conservative treatment: document trials of standard therapies, duration, and outcomes.
Prior authorization information: include device model, manufacturer, FDA product code, and any PDAC verification (E0770 for select FES devices).
Prior authorization recommended for NMES and other ES modalities when used for extended, nonstudy-concordant, or off-label indications.
Prior Conservative Care and Trial Requirements
Conservative therapy trial required before considering implantable restorative neurostimulation
A conservative therapy trial (greater than 90 days) including at least one course of physical therapy and medical management is required before considering implantable restorative neurostimulation.
Restorative neurostimulation prerequisite: Conservative therapy trial required before considering implantable restorative neurostimulation>90 days
Include at least one attempt of physical therapy and medical management
Definitions of Modalities and Devices
Electrical stimulation modalities deliver a range of waveforms to produce muscle contraction, modulate pain perception, or theoretically facilitate tissue repair. FES targets intact motor pathways to produce coordinated contractions for functional tasks (e.g., ambulation), while NMES targets specific muscles to prevent atrophy or augment strength during rehabilitation. Other modalities vary in invasiveness and mechanism and are described separately in the policy.
inv-117: FES definition
DefinitionFunctional Electrical Stimulation (FES): direct application of electric current to intact nerve fibers to cause involuntary but purposeful contractions to enable or enhance functional activities (standing, ambulation, grasping, respiration, etc.)
Application modeElectrodes may be transcutaneous or surgically implanted along with a stimulator
Therapeutic vs FunctionalTherapeutic FES for resistive exercise/cardiovascular conditioning; Functional FES to enable/augment functional tasks
inv-118: NMES definition
Typical Treatment Durations and Session Counts Observed in Studies
inv-169: NMES/FES treatment course (protocol-based durations in RCTs)
Typical NMES/FES RCT courseProtocol-based durations in many RCTs: daily sessions over weeks (examples: daily sessions for up to 6–12 weeks in several trials)
Early postoperative protocolsSome postoperative NMES trials applied daily sessions for 5–7 days immediately post-op (e.g., Takino et al.)
Adjunctive useTrials frequently delivered NMES/FES as adjuncts to supervised rehabilitation rather than as standalone treatments
inv-170: NMES course durations in studies varied
Study variabilityNMES course durations in studies varied widely — from single short hospital courses (days) to multi-week outpatient programs; protocols heterogeneous across indications
Postoperative example
Imaging and Procedural Guidance Notes
Documentation Required
implantation/revision of neurostimulator electrodes (CPTs) - fluoroscopy when performed
When implanting or revising neurostimulator electrodes (CPT 63663, 63664), fluoroscopy is referenced 'when performed' per CPT descriptors; include operative imaging notes if used.
If fluoroscopy was used during implantation or revision, document fluoroscopy use in operative report.
Align claim with CPT descriptor noting imaging 'when performed'.
Note
outcome assessment - no specific imaging mandated
Outcome assessment in trials used objective functional measures but no specific imaging modality is mandated by the policy for follow‑up; document clinical outcome measures rather than routine imaging requirements.
Provide functional outcome measures (6MWT, MRC strength, VAS) rather than routine imaging unless clinically indicated.
Modalities Considered Not Medically Necessary / Not Covered
The policy lists a set of modalities that are considered not covered / not medically necessary due to insufficient or low‑quality evidence. Key examples include IFT, MENS, PENS/PENFS, PNS, PSFS/PNFS, PES/PEMF, restorative neurostimulation, scrambler therapy, translingual stimulation, and manufacturer‑specific systems lacking published studies. Routine use of NMES/FES in some settings (e.g., universal ICU early rehabilitation) and home‑based FES for SCI rehabilitation are also identified as unsupported where evidence is lacking.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Unproven modalities: Translingual stimulation for gait rehabilitation (TS/PoNS)
Insufficient evidence; used adjunctively in trials
SCI - long-term FES cycling benefits:
Sadowsky et al. (2013) cohort found substantial gains in neurological scores, muscle mass, strength, and QOL with FES cycling versus ROM/stretching controls.
single-center cohort, nonrandomized
SCI - ES + PRT trial: Harvey et al. (2010) RCT showed ES superimposed on PRT increased voluntary quadriceps strength versus control, but clinical importance uncertain and role of ES versus PRT alone unclear.
small RCT
CP - FES for foot drop and gait: Multiple RCTs and systematic reviews show mixed results: some improvements in gait kinematics, stride length and step length, early functional benefits, but heterogeneity, small samples, and concerns about retention/blinding limit conclusions.
evidence supports potential role but not definitive activity/participation improvements
CVA - FES cycling early subacute: Galvão et al. (2024) meta-analysis reported benefits in trunk control and walking distance when FES cycling was combined with exercise; FES alone provided similar benefits to exercise for other motor outcomes; evidence rated low-to-moderate quality.
limited trials and heterogeneity
ICU and mechanically ventilated patients:
High-quality RCTs reported no improvement in long-term physical disability or ICU discharge muscle strength when NMES was added to standardized early rehabilitation in critically ill mechanically ventilated patients.
RCT evidence showing no benefit
Negative findings suggest careful selection for ICU NMES use
Pediatric cerebral palsy: Multiple RCTs and systematic reviews indicate NMES/FES can improve strength, muscle volume, gait kinematics and functional mobility in children with spastic CP, though dosage and protocols vary and optimal parameters are unknown.program durations ranged from 4–48 weeks in reviewed studies
Evidence supports individualized use to improve mobility and strength
Post-stroke (NMES + adjunctive therapies): Meta-analyses suggest NMES combined with swallowing or mirror therapy can improve swallowing function and walking parameters post-stroke versus conventional therapy, though evidence quality and heterogeneity vary across outcomes.treatment courses varied (2–12 weeks for dysphagia)
Recommend use as adjunct to conventional therapy
variable (subacute or chronic settings)
Heterogeneity and risk of bias noted
Prevention/mitigation of postsurgical muscle weakness: Early NMES in hospitalized or postsurgical adults showed small-to-moderate effects on muscle strength, size, and function and reduced decline in knee extensor strength when applied early postoperatively.daily sessions during hospitalization (e.g., postoperative days 1–7)
Heterogeneous protocols
COPD and ventilated patients: NMES in COPD and mechanically ventilated patients may improve quadriceps strength and some functional endpoints and reduce ventilation time in small trials; evidence quality low and not a replacement for pulmonary rehabilitation.variable
Mixed meta-analytic conclusions
Interferential therapy (IFT) for NSCLBP and knee OA: Some systematic reviews report short-term reductions in pain and disability versus placebo, but no consistent long-term benefit and heterogeneity of protocols limit strong coverage conclusions.
May justify short-term symptom relief in selected cases after conservative therapy
Other musculoskeletal indications: Trials and reviews show mixed results across conditions; device-specific systems without published studies lack support and may not be covered.
Coverage contingent on adequate evidence and documented response
TENS comparative findings: Several RCTs report TENS produces immediate and short-term improvements and in some comparisons was superior to IFT; consider TENS as first-line noninvasive electrical modality for certain musculoskeletal indications.
Consider before escalating to less-proven modalities
Guideline positions: Professional guidance is mixed: AAOS notes feasibility but limited recommendation; NICE recommends against PENS for low back pain; AAN/AANEM/AAPMR consider PENS an option for painful diabetic neuropathy.
Minimum independent standing tolerance>= 3 minutes of unsupported standing
Transfer abilityAbility to transfer independently (required for device use)
Hand/finger functionSufficient hand and finger function to manipulate device controls
Consider prior authorization for extended or non‑study‑concordant use of implantable or percutaneous systems (PNS, PENS, PENFS) due to limited/variable evidence.
Prior authorization recommended for percutaneous electrical stimulation (PENS) and percutaneous peripheral nerve stimulation (PNS) when used for chronic pain indications.
Prior authorization advisable for PNS/PES/PENFS given evidence limitations and to ensure appropriate patient selection and documentation.
Evidence‑limited prior authorization: therapies with insufficient or mixed evidence (e.g., restorative neurostimulation for some populations, home‑based FES for SCI outside CMS‑verified indications) may prompt prior auth or peer‑to‑peer review.
Insufficient evidence risk: modalities listed as unproven (IFT for many musculoskeletal indications, MENS, scrambler therapy, restorative neurostimulation for some indications, etc.) carry an increased risk of denial without strong supporting documentation.
No explicit prior authorization or denial: presence of a device FDA clearance/approval does not guarantee coverage — verify state and contract requirements; some TENS/NMES supplies may be payable per Nebraska DMEPOS rules when criteria are met.
Multiple health technology assessments (Hayes, ECRI, NICE) and systematic reviews inform prior authorization and stepwise therapy expectations — include relevant HTA citations with requests when available.
Nebraska Department of Health and Human Services: follow Code 471-7-000 DMEPOS criteria for medical necessity, device classification, and supplier requirements when requesting coverage.
DefinitionNeuromuscular Electrical Stimulation (NMES): transcutaneous application of electrical currents to cause muscle contractions to promote reinnervation, prevent disuse atrophy, relax spasms, and promote voluntary control
Typical targetsApplied to specific muscles (e.g., quadriceps) as part of rehabilitation protocols
Clinical contextsUsed for muscle rehabilitation, ICU-acquired weakness prevention, and adjunctive postsurgical recovery in trials
inv-119: IFT / MENS / PENS / PENFS / PSFS / PES definitions
IFTInterferential Therapy (IFT): medium-frequency pulsed currents delivered via surface electrodes producing a low-frequency current for deeper penetration; proposed for musculoskeletal pain
MENSMicrocurrent Electrical Nerve Stimulation (MENS): microampere-range, sub-sensory currents intended for pain relief and wound healing
PENS/PNTPercutaneous Electrical Nerve Stimulation (PENS)/Percutaneous Neuromodulation Therapy (PNT): acupuncture-like needles connected to external stimulator inserted percutaneously near pain site
PENFS/PSFS/PESIncludes percutaneous electrical nerve field stimulation (PENFS), peripheral subcutaneous field stimulation (PSFS/PNFS), and pulsed electrical stimulation (PES) — techniques vary from auricular field stimulation to implanted subcutaneous arrays and pulsed EM/elec fields
inv-120: PSFS / PNFS definition
DefinitionPSFS / PNFS: Peripheral Subcutaneous Field Stimulation — electrode arrays implanted in subcutaneous tissue of the painful area to stimulate cutaneous nerve endings rather than identified peripheral nerves
Use-caseUsed when the painful field is not well defined or does not align with a single peripheral nerve
DistinctionDifferent from PNS which targets specific peripheral nerves; PSFS targets tissue/field-level innervation
inv-121: PES definition
DefinitionPulsed Electrical Stimulation (PES): noninvasive pulsed electrical or electromagnetic fields hypothesized to facilitate bone/cartilage repair and alter inflammatory cell function
Proposed mechanismElectrostatic/electrodynamic fields may influence chondrocyte/osteoblast activity and cellular signaling
Evidence statusEvidence insufficient to support routine use for pain; robust RCTs needed
inv-122: restorative neurostimulation definition
DefinitionRestorative neurostimulation: implantable leads stimulate the multifidus to restore neuromuscular control in mechanical chronic low-back pain (example: ReActiv8)
Device exampleReActiv8 Implantable Neurostimulation System — targets L2 medial branch for bilateral multifidus stimulation; FDA PMA granted
Indication/contextIntended for patients with multifidus dysfunction refractory to >90 days conservative care and not candidates for spine surgery
inv-123: Scrambler Therapy definition
DefinitionScrambler Therapy (ST): noninvasive transdermal therapy applying continuously changing nonlinear waveforms via dermatomal electrode placement to deliver 'non‑pain' information for symptomatic relief of chronic neuropathic pain
Typical protocolCommonly delivered as 30–50 minute sessions over ~10 working days in trials
Evidence statusOverall evidence low-to-very-low quality and insufficient for routine recommendation outside trials
inv-124: TENS definition
DefinitionTranscutaneous Electrical Nerve Stimulation (TENS): surface electrodes deliver current to decrease perception of pain via afferent inhibition and/or endorphin release; distinct from NMES (which elicits muscle contraction)
Typical useUsed for symptomatic pain control as a noninvasive modality and often compared to IFT in trials
Regulatory/category noteTENS devices are regulated as Class II devices by FDA
inv-125: TLS definition
DefinitionTranslingual Stimulation (TLS / PoNS): noninvasive neuromuscular tongue stimulation delivering electrical input to trigeminal/facial pathways intended to promote neuroplasticity when combined with targeted physical therapy
Regulatory statusPoNS received De Novo approval for short-term adjunct to supervised therapeutic exercise for gait deficit in certain MS patients
Study contextTrials typically delivered TLNS plus physical therapy in patients who had plateaued with prior rehab
inv-126: TLS definition
DefinitionTranslingual stimulation (TLS/PoNS) indicated as short-term adjunct to supervised therapeutic exercise for gait deficits in certain MS patients per FDA De Novo labeling
Usage constraintPrescribed for adults 22+ and intended as adjunct to supervised therapy, not as standalone treatment
Evidence statusECRI concluded evidence inconclusive; trials often combined device with PT
inv-127: CCFES definition
DefinitionContralaterally Controlled Functional Electrical Stimulation (CCFES): form of FES where voluntary movement of the nonparetic limb controls stimulation of the paretic limb to assist task-relevant movements (e.g., hand opening)
Clinical findingsRCTs/meta-analyses report CCFES can improve upper-extremity outcomes versus cyclic NMES in some populations
Study contextsStudied in subacute and chronic stroke with task-oriented therapy adjuncts
inv-128: MeCFES definition
DefinitionMyoelectric continuous control FES (MeCFES): FES controlled by volitional myoelectric signals to assist task-oriented therapy for upper limb rehabilitation post-stroke
Clinical evidenceMeCFES as adjunct to task-oriented therapy showed improvements in some subacute stroke subjects vs conventional TOT
Operational noteRequires detection of volitional myoelectric signals to modulate stimulation in real time
inv-129: FES (functional electrical stimulation)
Functional contextFES (functional electrical stimulation) applied during functional tasks (e.g., gait, cycling) to elicit coordinated contractions improving mobility or cardiopulmonary conditioning
Delivery modesMay be delivered transcutaneously or with implanted electrodes; used for ambulation, grasping, bowel/bladder function, and FES cycling
Evidence notesFES is proven and medically necessary for lower limb paralysis due to SCI when specific eligibility criteria are met
NMES purposeApplied to specific muscles to cause contractions for reinnervation, prevent atrophy, relax spasms, and augment strength training as part of rehabilitation
Clinical trial contextsUsed in ICU, postoperative TKA/THR, ACL rehab and swallowing/dysphagia trials with variable protocols
Evidence noteSome RCTs show early post-op NMES improves quadriceps strength and function; effects often most pronounced early after intervention
inv-131: CCFES (Contralaterally Controlled FES)
DefinitionCCFES (Contralaterally Controlled FES): nonparetic limb movement controls stimulation of paretic limb to produce coordinated task-specific movements
Clinical trial findingsTrials show CCFES can improve manual dexterity vs cyclic NMES in some stroke populations, especially subacute or moderate impairment
ImplementationTypically used with home exercise and lab-based functional task practice over multi-week programs
inv-132: NMES (ICU/hospital use)
ICU/hospital useNMES applied in ICU or hospital settings aims to prevent/reverse acquired disability and muscle atrophy; study protocols vary widely in duration and frequency
OutcomesSystematic reviews report small effects on muscle strength/size and mixed effects on function; some RCTs show mitigation of postsurgical weakness when applied early
Evidence limitationsHeterogeneous protocols, variable bias, and inconsistent long-term functional benefits across studies
inv-133: IFT / IFC definition
IFT / IFC definitionInterferential Therapy (IFT/IFC): medium-frequency electrical currents delivered via surface electrodes intended for deeper tissue penetration to relieve musculoskeletal pain; evidence mixed and short-term benefits reported
Clinical findingsSystematic reviews report probable short-term pain/disability reduction versus placebo but inconsistent benefit when added to standard care
GuidanceNICE recommends against offering IFT for some indications (e.g., knee OA, chronic primary pain) due to insufficient evidence
inv-134: TEAS definition
TEAS definitionTranscutaneous Electrical Acupoint Stimulation (TEAS): noninvasive stimulation of acupoints often used perioperatively; trials show reduced short-term opioid consumption and postoperative pain within first 24 hours
Perioperative evidenceMeta-analyses including many RCTs report reduced opioid use and lower early postoperative pain scores; effects mostly short-term
Typical useIncorporated into multimodal perioperative analgesia in trials; protocols heterogeneous
inv-135: MENS / Microcurrent Therapy (MET)
MENS / MET definitionMicrocurrent Electrical Nerve Stimulation (MENS/MET): low-amplitude microcurrent therapy delivering sub-sensory microampere currents studied for myofascial and joint pain
EvidenceSmall RCTs and meta-analyses report modest short-term pain reductions but studies are few and heterogeneous
Regulatory noteMENS devices are often categorized with TENS for regulatory purposes though mechanisms differ substantially
inv-136: PENS definition
DefinitionPercutaneous Electrical Nerve Stimulation (PENS): minimally invasive needle-based stimulation (electroacupuncture/electrical intramuscular stimulation) inserted percutaneously near painful structures and connected to external power
Typical protocolsStudies report immediate moderate effects on pressure pain thresholds; sessions range from single to multiple (up to 16) with short-term outcomes predominating
Clinical noteSome trials used ultrasound guidance for nerve targeting (e.g., median nerve in CTS)
inv-137: IFT (Interferential Therapy)
IFT evidence summaryInterferential Therapy (IFT) evaluated for musculoskeletal pain with some trials showing immediate/short-term pain relief versus placebo, but inconsistent added benefit when combined with standard therapy
Comparative findingsIFT often shows no significant advantage over other modalities (TENS, laser) when added to standard care
RecommendationMore robust RCTs needed; NICE guidance advises against routine offering for some conditions
inv-138: PENS (alternate)
PENS (alternate)PENS shows immediate moderate effects on mechanical hyperalgesia and short-term pain; systematic reviews/meta-analyses find heterogenous protocols and limited long-term benefit
Session countsMost PENS studies are single-session to a few sessions; some trials included up to 16 sessions
Evidence cautionAuthors recommend well-designed RCTs with longer follow-up to determine durability and optimal parameters
inv-139: PENFS definition
PENFS definitionPercutaneous Electrical Nerve Field Stimulation (PENFS): auricular or other percutaneous field approaches that stimulate nerve fields rather than discrete peripheral nerves
Typical courseApplied typically in short courses (days–weeks) in pediatric DGBI and other disorders; registry and small studies report symptom improvements
Evidence statusOverall quality weak and limited; controlled trials few and larger RCTs needed
inv-140: TEAS (alternate)
TEAS (alternate)Transcutaneous electrical acupoint stimulation reduces early postoperative pain and opioid consumption; effects largely within first 24 hours
Study scaleNumerous RCTs (e.g., 76 RCTs in perioperative TEAS reviews) support short-term benefits though heterogenous protocols limit generalizability
Clinical roleReasonable as adjunct in multimodal perioperative analgesia based on current evidence
inv-141: PENFS (alternate)
PENFS (alternate)Auricular/percutaneous neuromodulation applied in short courses for pediatric DGBI shows symptom and QoL improvements in observational registries and small studies
LimitationsEvidence limited by lack of controls, heterogenous populations, and short follow-up
RecommendationLarger placebo-controlled trials recommended to validate efficacy and durability
inv-142: PNS definition
PNS definitionPercutaneous Peripheral Nerve Stimulation (PNS): placement of leads targeting specific peripheral nerves (e.g., femoral, sciatic, saphenous, medial branch) for chronic or postoperative pain, often with a temporary trial period
Trial durationsTemporary percutaneous lead trials in studies varied (e.g., 60 days, leads left up to 8 weeks)
Evidence statusEvidence small, heterogeneous, and low quality; larger RCTs needed to confirm efficacy
inv-143: PEMF/PES definition
PEMF/PES definitionPulsed Electromagnetic Field (PEMF) / Pulsed Electrical Stimulation (PES): noninvasive modalities delivering pulsed electromagnetic or electrical fields intended to modulate tissue/nerve activity for pain or healing
Proposed effectsIntended to modulate tissue repair, cartilage/bone cell function and inflammatory responses via induced fields
Evidence statusCurrent evidence insufficient to support routine use for chronic pain indications; more robust trials needed
inv-144: PNS (alternate)
PNS (alternate)Implantable and percutaneous PNS approaches exist; current evidence for many indications remains limited and heterogeneous, requiring further large RCTs
Clinical implicationTemporary percutaneous PNS trials commonly used to assess response prior to longer-term implantation
Regulatory/evidence noteDevice-specific assessments (ECRI, Hayes) highlight evolving evidence and need for larger comparative studies
inv-145: PES/PEMF (alternate)
PES/PEMF (alternate)PES/PEMF deliver pulsed electromagnetic/electrical fields intended for tissue healing or pain modulation; some small comparative studies report short-term benefits but overall evidence is inconsistent
Research recommendationWell-designed prospective RCTs comparing PES/PEMF to placebo/standard care are needed
inv-146: restorative neurostimulation (alternate)
Restorative neurostimulation (alternate)Implantable systems (e.g., ReActiv8) stimulate multifidus to restore neuromuscular control in refractory CLBP; evidence includes one fair RCT and observational long-term follow-up with limitations
Patient selectionStudies enrolled patients refractory to >90 days of conservative care and not surgical candidates
Evidence caveatECRI and HTAs note inconclusive evidence and call for independent larger comparative studies
inv-147: Restorative Neurostimulation (ReActiv8)
Device exampleReActiv8 Implantable Neurostimulation System: implantable restorative neurostimulator targeting bilateral L2 medial branch to stimulate multifidus; FDA PMA granted
IndicationFor adults with intractable CLBP associated with multifidus dysfunction who failed medications and physical therapy and are not candidates for spine surgery
Evidence summaryOne randomized sham-controlled trial (Gilligan 2021) with subsequent long-term observational follow-up shows improvements but with risk of bias and attrition
inv-148: Scrambler Therapy (ST / TEMPR)
Scrambler Therapy (ST / TEMPR)Noninvasive transcutaneous electronic modulation delivering variable nonlinear waveforms to dermatomal sites for chronic neuropathic pain; common trial protocols are 30–50 min sessions over ~10 working days
EvidenceSystematic reviews/meta-analyses and HTAs conclude overall evidence low-quality and insufficient for routine use outside clinical trials
Typical outcomesSome trials report marginal or short-term pain reduction and decreased analgesic use; methodological limitations common
inv-149: Translingual Stimulation (TLNS / PoNS)
Translingual Stimulation (TLNS / PoNS)Portable neuromodulation involving tongue stimulation via a mouthpiece to activate trigeminal/facial pathways, used adjunctively with targeted physical therapy for gait/balance deficits
Regulatory statusPoNS granted De Novo approval for short-term adjunct to supervised therapeutic exercise for gait deficit in certain MS patients
Trial contextRCTs often combined TLNS with physical therapy in patients plateaued after prior rehab; evidence inconclusive and limited by small trials
PoNS (alternate)PoNS device indicated as short-term adjunct to supervised therapeutic exercise for gait deficit in certain MS patients (FDA De Novo) — intended for prescription use in adults ≥22 years
Clinical trial designTrials frequently enroll patients with chronic balance/gait deficits who completed prior PT and use TLNS plus targeted PT protocols
ReActiv8 alternate summaryReActiv8 is an implantable restorative neurostimulation system with FDA PMA that targets multifidus dysfunction in refractory CLBP; available evidence includes one RCT and several observational follow-ups showing benefit but limited by attrition and risk of bias
Patient selection criteriaStudies required >90 days conservative management, prior PT attempt, and patients not surgical candidates
RecommendationAdditional independent comparative trials recommended to confirm safety and efficacy
FES definition / refsFES: direct coordinated electrical stimulation of intact motor neurons to produce purposeful contractions for function or therapy; see device/coverage guidance (CMS FES resources) and trial literature
Reference examplesHayes EARB and multiple systematic reviews cited for FES applications in SCI, stroke, CP and CHF contexts
Regulatory/coding noteCMS PDAC-verified FES devices and HCPCS coding guidance are referenced in policy materials
PNS definition / refsPercutaneous Peripheral Nerve Stimulation (PNS): percutaneous lead placement targeting named peripheral nerves for chronic or postoperative pain; evidence includes small RCTs, case series and device assessments (ECRI, Hayes)
Device examplesStimRouter, SPRINT, and other percutaneous PNS systems cited in device sections and RCTs
Evidence noteECRI and Hayes report limited/heterogeneous evidence and call for larger robust trials
Modalities coveredElectrical stimulation modalities include FES, NMES, IFT/IFC, PES/PEMF, PNS, PSFS/PNFS, PENS/PENFS, MENS, Scrambler Therapy, TENS, TLS/PoNS, and restorative neurostimulation
MechanismsMechanisms range from motor neuron activation for functional movement (FES/NMES) to sub-sensory microcurrents (MENS), percutaneous needle stimulation (PENS), field stimulation (PENFS/PSFS), and pulsed EM fields (PES/PEMF)
Evidence generalizationEvidence strength and clinical support vary widely by modality and indication; many modalities lack high-quality RCT data for routine coverage
Takino et al. NMES RCT: daily 60-minute sessions from postoperative day 1 to day 7 showed mitigation of postsurgical muscle weakness
ICU/hospital examplesSome ICU studies continued NMES for hospital stay or until discharge; outcomes and durations inconsistent across trials
inv-171: PENS/TEAS/MENS session counts
Session counts (PENS/TEAS/MENS)PENS/TEAS/MENS studies often range from single sessions up to ~16 sessions; effects are commonly immediate or short-term in trials
TEAS perioperative evidenceTEAS perioperative trials often delivered daily sessions in the first 24–72 hours post-op with reduced opioid consumption and short-term pain improvements
Evidence limitationHeterogeneous protocols and short follow-up limit generalizability of optimal session counts
inv-172: No explicit frequency limits provided; study variability noted
Frequency limits statementNo explicit frequency limits are specified in this policy excerpt; study session counts vary from single sessions to multiple weekly sessions depending on modality and indication
Implication for authorizationPrior authorization or documentation may be required for extended or nonstudy-concordant treatment courses
Provider noteDocument intended treatment course, parameters, and objective outcome measures when requesting prolonged therapy
Temporary percutaneous PNS trialsTemporary lead treatment durations in trials varied (examples: 60-day trials; leads left in place up to 8 weeks in some studies)
Daily use recommendationsSome studies instructed percutaneous PNS use for 6–12 hours/day during the trial period
Follow-up after trialTrials often included extended follow-up to assess durability after temporary lead removal
Reference noteFunctional Electrical Stimulation and peripheral nerve stimulation frequency limits are not explicitly specified in referenced coding/guidance sections; refer to individual trial protocols and state DMEPOS criteria
Coding guidanceCMS and HCPCS coding resources are cited for FES device identification and coverage implications
Clinical implicationTreatment duration and frequency should align with evidence-based study protocols or documented clinical rationale
Documentation Required
NMES for dysphagia - imaging not routinely required
For NMES used to treat dysphagia, outcome assessment in studies sometimes used video fluoroscopic swallowing studies (VFSS); VFSS is not routinely required but can be included as an objective outcome in documentation when available.
Attach VFSS results if used to document baseline swallowing impairment or treatment response.
Note
Note
Documentation Required
PENS for carpal tunnel - ultrasound guidance mentioned
Ultrasound guidance was mentioned in PENS procedural trials (e.g., median nerve targeting for carpal tunnel); when ultrasound guidance is used, document the guidance method and operator competency.
Include ultrasound guidance notes and operator experience in procedure documentation.
If guidance was not used, state rationale and targeting method.
Documentation Required
PNS lead placement - imaging mentions but no mandated protocol
Studies of PNS lead placement reference targeting specific peripheral nerves and sometimes used imaging guidance, but the policy does not mandate a specific imaging protocol; document lead targets and any imaging guidance used.
Describe targeted nerve(s) (femoral, sciatic, saphenous, medial branch) and whether imaging guidance was applied.
Provide procedural notes and lead dwell time if temporary trial leads were used.
Documentation Required
Restorative neurostimulation (ReActiv8) imaging or physiologic testing referenced
Restorative neurostimulation (ReActiv8) evidence and labeling reference imaging or physiologic testing for multifidus dysfunction as part of patient selection; include such testing if available to support selection.
Provide imaging or physiologic test results documenting multifidus dysfunction when available.
Reference device PMA indication for patient selection criteria.
Documentation Required
percutaneous electrical nerve stimulation - some trials specify ultrasound guidance
Some percutaneous electrical nerve stimulation trials specified ultrasound guidance; when such guidance is used in clinical practice, document the guidance technique in the procedure note to align with study methods.
Document ultrasound use and rationale for targeting in procedural records.
If study protocols used guidance, reference the protocol when justifying technique.